Referências

1. Giustino G, Baber U, Sartori S, Mehran R, Mastoris I, Kini AS, Sharma SK, Pocock SJ, Dangas GD., Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials, J Am Coll Cardiol, 65, pp. 1298-1310, (2015)
2. Palmerini T, Benedetto U, Bacchi-Reggiani L, Della Riva D, Biondi-Zoccai G, Feres F, Abizaid A, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Genereux P, Bhatt DL, Orlandi C, De Servi S, Petrou M, Rapezzi C, Stone GW., Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials, Lancet, 385, pp. 2371-2382, (2015)
3. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN, 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS), Eur Heart J, 39, pp. 213-260, (2018)
4. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O'Gara PT, Sabatine MS, Smith PK, Smith SC, Halperin JL, Levine GN, Al-Khatib SM, Birtcher KK, Bozkurt B, Brindis RG, Cigarroa JE, Curtis LH, Fleisher LA, Gentile F, Gidding S, Hlatky MA, Ikonomidis JS, Joglar JA, Pressler SJ, Wijeysundera DN., 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, J Thorac Cardiovasc Surg, 152, pp. 1243-1275, (2016)
5. Collet JP, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Juni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM, 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, Eur Heart J, 42, pp. 1289-1367, (2021)
6. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, Nishikawa H, Hiasa Y, Muramatsu T, Meguro T, Inoue N, Honda H, Hayashi Y, Miyazaki S, Oshima S, Honda T, Shiode N, Namura M, Sone T, Nobuyoshi M, Kita T, Mitsudo K, Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation, Circulation, 119, pp. 987-995, (2009)
7. Levine GN, Jeong YH, Goto S, Anderson JL, Huo Y, Mega JL, Taubert K, Smith SC, Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI, Nat Rev Cardiol, 11, pp. 597-606, (2014)
8. Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, Takayama M, Kitagawa K, Nishikawa M, Miyazaki S, Nakamura M., Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study, Circ J, 78, pp. 1684-1692, (2014)
9. Nakamura M, Kimura K, Kimura T, Ishihara M, Otsuka F, Kozuma K, Kosuge M, Shinke T, Nakagawa Y, Natsuaki M, Yasuda S, Akasaka T, Kohsaka S, Haze K, Hirayama A., JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease, Circ J, 84, pp. 831-865, (2020)
10. Li YH, Lee CH, Huang WC, Wang YC, Su CH, Sung PH, Chien SC, Hwang JJ., 2020 Focused Update of the 2012 Guidelines of the Taiwan Society of Cardiology for the Management of ST-Segment Elevation Myocardial Infarction, Acta Cardiol Sin, 36, pp. 285-307, (2020)
11. Nakamura M, Morino Y, Kakuta T, Hata Y, Takamisawa I, Tanabe K, Anzai H, Takahashi A, Kadota K, Suzuki H, Wakatsuki T, Okayama H, Yamashita J, Akasaka T, Yokoi H, Nakagami T, Higuchi Y, Yamaguchi J, Kimura T, Harada A, Kuroda T, Takita A, Iijima R, Murakami Y, Saito S., Monotherapy With Prasugrel After Dual-Antiplatelet Therapy for Japanese Percutaneous Coronary Intervention Patients With High Bleeding Risk- A Prospective Cohort Study (PENDULUM mono Study), Circ J, 85, pp. 27-36, (2020)
12. Nakamura M, Kadota K, Takahashi A, Kanda J, Anzai H, Ishii Y, Shibata Y, Yasaka Y, Takamisawa I, Yamaguchi J, Takeda Y, Harada A, Motohashi T, Iijima R, Uemura S, Murakami Y, Relationship Between Platelet Reactivity and Ischemic and Bleeding Events After Percutaneous Coronary Intervention in East Asian Patients: 1-Year Results of the PENDULUM Registry, J Am Heart Assoc, 9, (2020)
13. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, Clinical end points in coronary stent trials: a case for standardized definitions, Circulation, 115, pp. 2344-2351, (2007)
14. Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-Reggiani L, Smits PC, Vlachojannis GJ, Jensen LO, Christiansen EH, Berencsi K, Valgimigli M, Orlandi C, Petrou M, Rapezzi C, Stone GW., Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis, J Am Coll Cardiol, 65, pp. 2496-2507, (2015)
15. Kereiakes DJ, Meredith IT, Windecker S, Lee Jobe R, Mehta SR, Sarembock IJ, Feldman RL, Stein B, Dubois C, Grady T, Saito S, Kimura T, Christen T, Allocco DJ, Dawkins KD., Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II Randomized Trial, Circ Cardiovasc Interv, (2015)
16. Zanchin C, Ueki Y, Zanchin T, Haner J, Otsuka T, Stortecky S, Koskinas KC, Siontis GCM, Praz F, Moschovitis A, Hunziker L, Valgimigli M, Pilgrim T, Heg D, Windecker S, Raber L., Everolimus-Eluting Biodegradable Polymer Versus Everolimus-Eluting Durable Polymer Stent for Coronary Revascularization in Routine Clinical Practice, JACC Cardiovasc Interv, 12, pp. 1665-1675, (2019)
17. Kogame N, Guimaraes PO, Modolo R, De Martino F, Tinoco J, Ribeiro EE, Kawashima H, Ono M, Hara H, Wang R, Cavalcante R, Moulin B, Falcao BAA, Leite RS, de Almeida Sampaio FB, Morais GR, Meireles GC, Campos CM, Onuma Y, Serruys PW, Lemos PA., Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD: The ASET Pilot Study, JACC Cardiovasc Interv, 13, pp. 2251-2262, (2020)
18. Serruys PW, van Hout B, Bonnier H, Legrand V, Garcia E, Macaya C, Sousa E, van der Giessen W, Colombo A, Seabra-Gomes R, Kiemeneij F, Ruygrok P, Ormiston J, Emanuelsson H, Fajadet J, Haude M, Klugmann S, Morel MA., Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II), Lancet, 352, pp. 673-681, (1998)
19. Nakagawa Y, Nobuyoshi M, Yamaguchi T, Meguro T, Yokoi H, Kimura T, Hosoda S, Kanmatsuse K, Matsumori A, Sasayama S., Efficacy of abciximab for patients undergoing balloon angioplasty: data from Japanese evaluation of c7E3 Fab for elective and primary PCI organization in randomized trial (JEPPORT), Circ J, 73, pp. 145-151, (2009)
20. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO., 2018 ESC/EACTS Guidelines on myocardial revascularization, EuroIntervention, 14, 14, pp. 1435-1534, (2019)
21. Watanabe H, Morimoto T, Shiomi H, Natsuaki M, Kawai K, Kozuma K, Igarashi K, Kadota K, Tanabe K, Morino Y, Hibi K, Akasaka T, Abe M, Suwa S, Muramatsu T, Kobayashi M, Dai K, Nakao K, Tarutani Y, Fujii K, Kimura T, Impact of Angiographic Residual Stenosis on Clinical Outcomes After New-Generation Drug-Eluting Stents Implantation: Insights From a Pooled Analysis of the RESET and NEXT Trials, J Am Heart Assoc, 30, 7, (2018)
22. Diodati JG, Saucedo JF, French JK, Fung AY, Cardillo TE, Henneges C, Effron MB, Fisher HN, Angiolillo DJ., Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): a randomized controlled trial, Circ Cardiovasc Interv, 6, pp. 567-574, (2013)
23. Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, Sibbing D, So DYF, Trenk D, Alexopoulos D, Gurbel PA, Hochholzer W, De Luca L, Bonello L, Aradi D, Cuisset T, Tantry US, Wang TY, Valgimigli M, Waksman R, Mehran R, Montalescot G, Franchi F, Price MJ., International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies, Circulation, 136, pp. 1955-1975, (2017)
24. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, Fourth universal definition of myocardial infarction (2018), Eur Heart J, 40, pp. 237-269, (2019)
25. Moussa ID, Klein LW, Shah B, Mehran R, Mack MJ, Brilakis ES, Reilly JP, Zoghbi G, Holper E, Stone GW., Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI), J Am Coll Cardiol, 62, pp. 1563-1570, (2013)
26. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H., Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium, Circulation, 123, pp. 2736-2747, (2011)
27. Vranckx P, Valgimigli M, Juni P, Hamm C, Steg PG, Heg D, van Es GA, McFadden EP, Onuma Y, van Meijeren C, Chichareon P, Benit E, Mollmann H, Janssens L, Ferrario M, Moschovitis A, Zurakowski A, Dominici M, Van Geuns RJ, Huber K, Slagboom T, Serruys PW, Windecker S, Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial, Lancet, 392, pp. 940-949, (2018)
28. Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, Cha JY, Collier T, Dangas G, Dudek D, Dzavik V, Escaned J, Gil R, Gurbel P, Hamm CW, Henry T, Huber K, Kastrati A, Kaul U, Kornowski R, Krucoff M, Kunadian V, Marx SO, Mehta SR, Moliterno D, Ohman EM, Oldroyd K, Sardella G, Sartori S, Shlofmitz R, Steg PG, Weisz G, Witzenbichler B, Han YL, Pocock S, Gibson CM., Ticagrelor with or without Aspirin in High-Risk Patients after PCI, N Engl J Med, 381, pp. 2032-2042, (2019)
29. Kim BK, Hong SJ, Cho YH, Yun KH, Kim YH, Suh Y, Cho JY, Her AY, Cho S, Jeon DW, Yoo SY, Cho DK, Hong BK, Kwon H, Ahn CM, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y, Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial, JAMA, 323, pp. 2407-2416, (2020)
30. Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, Ohya M, Suwa S, Takagi K, Nanasato M, Hata Y, Yagi M, Suematsu N, Yokomatsu T, Takamisawa I, Doi M, Noda T, Okayama H, Seino Y, Tada T, Sakamoto H, Hibi K, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Hanaoka KI, Morino Y, Kozuma K, Kadota K, Furukawa Y, Nakagawa Y, Kimura T, Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial, JAMA, 321, pp. 2414-2427, (2019)
31. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE., A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators, N Engl J Med, 339, pp. 1665-1671, (1998)
32. Miyazaki Y, Suwannasom P, Sotomi Y, Abdelghani M, Tummala K, Katagiri Y, Asano T, Tenekecioglu E, Zeng Y, Cavalcante R, Collet C, Onuma Y, Serruys PW., Single or dual antiplatelet therapy after PCI, Nat Rev Cardiol, 14, pp. 294-303, (2017)
33. Freij A, Thorsen M., Ticagrelor versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, 361, pp. 1045-1057, (2009)
34. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, Prasugrel versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, 357, pp. 2001-2015, (2007)
35. Armstrong PC, Dhanji AR, Tucker AT, Mitchell JA, Warner TD., Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy, J Thromb Haemost, 8, pp. 613-615, (2010)
36. Armstrong PC, Leadbeater PD, Chan MV, Kirkby NS, Jakubowski JA, Mitchell JA, Warner TD., In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation, J Thromb Haemost, 9, pp. 552-561, (2011)
37. Alli O, Smith C, Hoffman M, Amanullah S, Katz P, Amanullah AM., Incidence, predictors, and outcomes of gastrointestinal bleeding in patients on dual antiplatelet therapy with aspirin and clopidogrel, J Clin Gastroenterol, 45, pp. 410-414, (2011)
38. Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, Eriksson B, Appelman-Eszczuk S, Langstrom G, Naesdal J, Serrano P, Singh M, Skelly MM, Hawkey CJ., Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin, Aliment Pharmacol Ther, 22, pp. 795-801, (2005)
39. Cryer B, Bhatt DL, Lanza FL, Dong JF, Lichtenberger LM, Marathi UK., Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial, Am J Gastroenterol, 106, pp. 272-277, (2011)
40. Chen WC, Lin KH, Huang YT, Tsai TJ, Sun WC, Chuah SK, Wu DC, Hsu PI., The risk of lower gastrointestinal bleeding in low-dose aspirin users, Aliment Pharmacol Ther, 45, pp. 1542-1550, (2017)
41. Levy DJ., Images in clinical medicine. An aspirin tablet and a gastric ulcer, N Engl J Med, 343, (2000)
42. Huang WY, Saver JL, Wu YL, Lin CJ, Lee M, Ovbiagele B., Frequency of Intracranial Hemorrhage With Low-Dose Aspirin in Individuals Without Symptomatic Cardiovascular Disease: A Systematic Review and Meta-analysis, JAMA Neurol, 76, pp. 906-914, (2019)
43. Vranckx P, Valgimigli M, Odutayo A, Serruys PW, Hamm C, Steg PG, Heg D, Mc Fadden EP, Onuma Y, Benit E, Janssens L, Diletti R, Ferrario M, Huber K, Raber L, Windecker S, Juni P, Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-Specified Analysis of the GLOBAL LEADERS Trial, J Am Heart Assoc, 10, (2021)
44. Natsuaki M, Morimoto T, Shiomi H, Kadota K, Tada T, Takeji Y, Matsumura-Nakano Y, Yoshikawa Y, Watanabe H, Yamamoto K, Imada K, Domei T, Yamaji K, Kaneda K, Taniguchi R, Ehara N, Nawada R, Toyofuku M, Shinoda E, Suwa S, Tamura T, Inada T, Matsuda M, Aoyama T, Sato Y, Furukawa Y, Ando K, Nakagawa Y, Kimura T, Effects of Acute Coronary Syndrome and Stable Coronary Artery Disease on Bleeding and Ischemic Risk After Percutaneous Coronary Intervention, Circ J, 85, pp. 1928-1941, (2021)
45. Franzone A, McFadden E, Leonardi S, Piccolo R, Vranckx P, Serruys PW, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, Diletti R, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, Petrov I, Garg S, Naber C, Prokopczuk J, Hamm C, Steg PG, Heg D, Juni P, Windecker S, Valgimigli M, Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting, J Am Coll Cardiol, 74, pp. 2223-2234, (2019)
46. Valgimigli M, Frigoli E, Heg D, Tijssen J, Juni P, Vranckx P, Ozaki Y, Moric MC, Chevalier B, Onuma Y, Windecker S, Tonino PAL, Roffi M, Lesiak M, Mahfoud F, Bartunek J, Hildick-Smith D, Colombo A, Stankovic G, Iniguez A, Schultz C, Kornowski R, Ong PJL, Alasnag M, Rodriguez AE, Moschovitis A, Laanmets P, Donahue M, Leonardi S, Smits PC, Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk, N Engl J Med, 385, pp. 1643-1655, (2021)
47. Valgimigli M, Gragnano F, Branca M, Franzone A, Baber U, Jang Y, Kimura T, Hahn JY, Zhao Q, Windecker S, Gibson CM, Kim BK, Watanabe H, Song YB, Zhu Y, Vranckx P, Mehta S, Hong SJ, Ando K, Gwon HC, Serruys PW, Dangas GD, McFadden EP, Angiolillo DJ, Heg D, Juni P, Mehran R., P2Y12 inhibitor monotherapy
48. or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials, BMJ, 373, (2021)
49. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E, Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial, Circulation, 116, pp. 2923-2932, (2007)
50. Aytekin A, Ndrepepa G, Neumann FJ, Menichelli M, Mayer K, Wohrle J, Bernlochner I, Lahu S, Richardt G, Witzenbichler B, Sibbing D, Cassese S, Angiolillo DJ, Valina C, Kufner S, Liebetrau C, Hamm CW, Xhepa E, Hapfelmeier A, Sager HB, Wustrow I, Joner M, Trenk D, Fusaro M, Laugwitz KL, Schunkert H, Schupke S, Kastrati A., Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention, Circulation, 142, pp. 2329-2337, (2020)